how many people take glp-1 use peaks in middle age, then drops at 65 how many glp-1 drugs are
Description
In addition to glycemic control, GLP-1 receptor agonists have beneficial other effects
On November 8, 2023, the FDA approved Zepbound for use in adults with obesity or those who are overweight with at least one weight-related condition
Nausea, constipation, diarrhea, vomiting, fatigue, reflux, and injection-site reactions are common across GLP-1 labels, but the useful tracking signal is context: dose timing, day after dose, dose increase, meal size, water, fiber, and symptom severity
Persistent symptoms may warrant a dose adjustment, a temporary acid-suppressing medication (like omeprazole), or investigation into whether an underlying condition like gastroesophageal reflux disease (GERD) is being unmasked by the tirzepatide's effects
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
